Uppsala professor warns TBE vaccine may need updating

TBE cases in Sweden have tripled over ten years despite rising vaccinations. Åke Lundkvist, professor of virology at Uppsala University, suspects the virus may have changed, reducing vaccine effectiveness. Researchers are now analyzing 12,000 ticks to investigate.

The number of reported TBE cases in Sweden has risen sharply over the past ten years. According to Folkhälsomyndigheten, cases increased from 238 in 2016 to 504 in 2025, with peaks like 595 in 2023 and a low of 274 in 2020. Vaccinations have risen at a similar pace.

Åke Lundkvist, professor of virology at Uppsala University, describes the trend as suspicious. "Something is fishy," he told SVT Nyheter. He suggests the vaccine may be losing effectiveness if the TBE virus has mutated. "The vaccine can become less effective if the virus causing the infection changes," Lundkvist explained.

To clarify, around 12,000 ticks collected by the Swedish public are being sent to Statens veterinärmedicinska anstalt (SVA). They will be analyzed in collaboration with Uppsala University's Zoonoscentret to compare current virus strains with those from previous years and the basis for existing vaccines.

Lundkvist stresses the need for vaccination. "Absolutely not [skip getting vaccinated], the vaccine works and it is the only important remedy we have today. We will find out if it can be even better," he said. The research aims to rule out other causes for the rise.

Relaterte artikler

Illustration of a crowded Swedish hospital amid flu surge, with rising case stats displayed.
Bilde generert av AI

Antall influensatilfeller øker kraftig i Sverige

Rapportert av AI Bilde generert av AI

Influensa har virkelig kommet til Sverige. I årets første uke ble 2131 tilfeller bekreftet, en økning på 22 prosent fra slutten av forrige uke. Utbredelsen vurderes til middels høyt nivå, ifølge Folkhälsomyndigheten.

Influensatilfeller i Sverige har doblet seg hver uke siden midten av november, drevet av den nye K-varianten av influensaviruset. Folkhälsomyndigheten rapporterer en rask økning, med tilfeller som stiger fra 403 til 808 på én uke. Alvorlige tilfeller, inkludert dødsfall og innleggelser på intensiv, har også steget fra lave nivåer.

Rapportert av AI

Researchers in China have developed a potent antibody that could combat severe fever with thrombocytopenia syndrome (SFTS), a tick-borne disease with a mortality rate of up to 30 percent. The discovery offers new hope for tackling this growing threat in East Asia.

Meningittutbruddet i Canterbury i Kent, Storbritannia, har eskalert med 29 infeksjoner og to dødsfall, noe som har ført til massevaksinering og utdeling av antibiotika. Myndighetene advarer mot mulig spredning utenfor Kent, mens svenske eksperter råder til årvåkenhet.

Rapportert av AI Faktasjekket

Scientists at the University of Queensland have captured the first near‑atomic, high‑resolution 3D images of the yellow fever virus, detailing how the surface of the long‑used vaccine strain differs from virulent, disease‑causing strains. The work sheds light on how the virus is recognised by the immune system and could support improved vaccines for yellow fever and related mosquito‑borne diseases.

Researchers at UC San Francisco have uncovered evidence showing how the Epstein-Barr virus may trigger immune responses in multiple sclerosis patients. The study reveals elevated levels of virus-targeting immune cells in the nervous systems of those with the disease. These findings, published in Nature Immunology, suggest potential new treatment avenues by targeting the virus.

Rapportert av AI

Measles infections in the United States hit their highest level in over three decades last year, with 2,242 confirmed cases. A surging outbreak in South Carolina, which has infected more than 600 people since October, threatens to surpass a major incident in West Texas. This development signals another challenging year for public health ahead.

 

 

 

Dette nettstedet bruker informasjonskapsler

Vi bruker informasjonskapsler for analyse for å forbedre nettstedet vårt. Les vår personvernerklæring for mer informasjon.
Avvis